SAFX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
XCF Global Inc (SAFX) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks significant positive momentum, has bearish technical indicators, and no strong proprietary trading signals. Additionally, while there are some positive developments, such as financing progress and analyst optimism, the company's financials remain weak, and the stock's near-term trend suggests potential downside.
The technical indicators for SAFX are bearish. The MACD histogram is negative and expanding, the RSI is neutral at 35.456, and the moving averages are in a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level of 0.37, with resistance levels at 1.085 and 1.306. Overall, the technical setup does not indicate a strong buying opportunity.
XCF Global raised $10 million for its plant conversion, fulfilling a key financing condition for a proposed business combination.
Analyst Craig Irwin raised the price target to $1.20, citing tangible progress and a strong endorsement from a collaboration with Axens.
USDA loan guarantee is considered an underappreciated strength by analysts.
The stock's technical indicators are bearish, with a negative MACD and bearish moving averages.
DevvStream's stock price decline reflects market caution regarding the proposed business combination.
SAFX has a projected negative trend in the near term, with a 70% chance of declining -2.65% in the next week and -6.62% in the next month.
In Q3 2025, XCF Global's revenue remained flat YoY at $9,553,439. However, net income improved significantly to -$12,514,966 (up 268.28% YoY), and EPS increased to -0.08 (up 300% YoY). Gross margin remained steady at 35.02%. Despite these improvements, the company is still operating at a loss, which raises concerns for long-term investors.
Roth Capital analyst Craig Irwin raised the price target from $0.40 to $1.20, maintaining a Neutral rating. The analyst cited tangible progress on the New Rise restart and a strong endorsement from Axens. However, the Neutral rating indicates caution, and the firm suggests buying only on clarity around plant economics or balance sheet improvements.
